Posted by Michael Wonder on 23 Aug 2022
Synlogic granted FDA fast track designation for SYNB1353 for the treatment of homocystinuria
23 August 2022 - Synlogic today announced that the U.S. FDA has granted fast track designation to SYNB1353 for the potential treatment of homocystinuria.
SYNB1353 is an engineered strain of the probiotic bacteria E. coli Nissle which consumes methionine within the gastrointestinal tract, preventing methionine absorption and conversion to homocysteine in plasma.
